Bildkälla: Stockfoto

BioInvent: First BI-1206 SC Data - Redeye

Redeye is optimistic about the new data from lymphoma patients treated with subcutaneous as well as intravenous BI-1206.

Redeye is optimistic about the new data from lymphoma patients treated with subcutaneous as well as intravenous BI-1206.
Börsvärldens nyhetsbrev
ANNONSER